{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:48:08Z","timestamp":1782150488726,"version":"3.54.5"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The clinical utility of many analgesics is limited by their nonselective action, which yields desired analgesia at the cost of significant off-target effects across multiple organ systems. Developing non-opioid therapies that act selectively on peripheral nociceptive pathways remains a key goal for achieving effective and safer pain management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Suzetrigine, a highly selective inhibitor of the voltage-gated sodium channel subtype 1.8 (NaV1.8), represents a novel class of nonopioid analgesics that recently granted the Food and Drug Administration approval for the treatment of moderate to severe acute pain. NaV1.8 is selectively expressed in peripheral sensory neurons, where it plays a critical role in transmitting nociceptive signals from tissue injury. In clinical studies, suzetrigine demonstrated analgesic efficacy comparable to hydrocodone\/acetaminophen, combined with the absence of abuse and addictive potential. High patient satisfaction, and a lack of serious adverse effects further support its role in multimodal analgesia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Suzetrigine shows significant potential to improve the treatment of moderate-to-severe acute pain of both surgical and nonsurgical origin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aco.0000000000001626","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:00:15Z","timestamp":1771401615000},"page":"456-460","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Suzetrigine, a novel nonopioid analgesic for acute pain"],"prefix":"10.1097","volume":"39","author":[{"given":"Nada","family":"Pej\u010di\u0107","sequence":"first","affiliation":[{"name":"Clinic for Anesthesiology and Intensive Therapy, University Clinical Center Nis, Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Stojanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Anesthesiology and Intensive Therapy, University Clinical Center Nis, Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radmilo","family":"Jankovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Anesthesiology and Intensive Therapy, University Clinical Center Nis, Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/ALN.0b013e31828866b3","article-title":"Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures.","volume":"118","author":"Gerbershagen","year":"2013","journal-title":"Anesthesiology"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/ALN.0000000000002238","article-title":"Persistent postsurgical pain: pathophysiology and preventative pharmacologic considerations.","volume":"129","author":"Richeb\u00e9","year":"2018","journal-title":"Anesthesiology"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/ph17081009","article-title":"Misuse, abuse and medication errors\u2019 adverse events associated with opioids\u2014a systematic review.","volume":"17","author":"Gustafsson","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R4-20260622","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/rapm-2021-103083","article-title":"A multisociety organizational consensus process to define guiding principles for acute perioperative pain management.","volume":"47","author":"Mariano","year":"2022","journal-title":"Reg Anesth Pain Med"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1113\/jphysiol.2011.224204","article-title":"Voltage-gated sodium channels at 60: structure, function and pathophysiology.","volume":"590","author":"Catterall","year":"2012","journal-title":"J Physiol"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective Nav1.8 pain signal inhibitor for the treatment of moderate to severe pain.","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"key":"R8-20260622","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1.8 with VX-548 for acute pain.","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"key":"R9-20260622","first-page":"1085","article-title":"Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials.","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"R10-20260622","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain.","volume":"18","author":"McCoun","year":"2025","journal-title":"J Pain Res"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1213\/ANE.0000000000007721","article-title":"Suzetrigine-induced metabolism of factor Xa inhibitors may increase risk of thrombosis in perioperative and pain patients.","volume":"141","author":"McCoy","year":"2025","journal-title":"Anesth Analg"},{"key":"R15-20260622","first-page":"729","article-title":"The effectiveness and value of suzetrigine for moderate to severe acute pain: a summary from the Institute for Clinical and Economic Review\u2019s Midwest Comparative Effectiveness Public Advisory Council.","volume":"31","author":"Nikitin","year":"2025","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:04:40Z","timestamp":1782147880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000001626","relation":{},"ISSN":["0952-7907","1473-6500"],"issn-type":[{"value":"0952-7907","type":"print"},{"value":"1473-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}